Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting ...

KZN to receive Lenacapavir,new long-acting HIV prevention injection. Minister Motsoaledi confirms rollout to 360 clinics, for 6-month protection dose ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

South Africa’s Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

JOHANNESBURG - Lenacapavir is described as a gamechanger in the fight against HIV/Aids. The long-acting prevention injection only needs to be administered twice a year. The National AIDS Council and ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.